Expanded therapeutic use for melanoma antibody

The monoclonal antibody ipilimumab, indicated for the treatment of adults with advanced melanoma, is now licensed for first-line use


The monoclonal antibody ipilimumab (Yervoy), indicated for the treatment of adults with advanced (unresectable or metastatic) melanoma, is now licensed for first-line use.1

Ipilimumab enhances T-cell mediated responses by blocking the inhibitory signal of cytotoxic T-lymphocyte antigen-4 (CTLA-4). This results in T-cell activation, proliferation and lymphocyte infiltration into tumours, leading to tumour cell death.1

Analysis of pooled data for ipilimumab from phase II and III trials in chemotherapy-naive patients (n=78) showed estimated one- and two-year survival rates of 54.1% (95% CI 42.5-65.6) and 32% (95% CI 20.7-42.9), respectively.

In two retrospective observational studies in treatment-naive patients receiving ipilimumab (n=120 and n=61), estimated
one-year survival rates were 59.5% (95% CI 50.1-67.8) and 49.3% (95% CI 35.6-61.6).1

Reference

1. Yervoy Summary of Product Characteristics, December 2013.


Read these next

New treatment for patients with advanced melanoma

New treatment for patients with advanced melanoma

Dabrafenib (Tafinlar) is a new treatment option for...

Survival rates in melanoma

Survival rates in melanoma

Subsequent melanomas in patients with multiple primary...

Clinical Review: Malignant melanoma

Clinical Review: Malignant melanoma

Early diagnosis of malignant melanoma is crucial because...


Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.